Company Quick10K Filing
Quick10K
Health Catalyst
10-Q 2019-06-30 Quarter: 2019-06-30
S-1 2019-06-27 Public Filing
8-K 2019-08-22 Earnings, Exhibits
TSRO Tesaro 2,486
REN Resolute Energy 801
CORVF Corvus Gold 196
RLJE RLJ Entertainment 69
WCUI Wellness Center 19
QTMM Quantum Materials 17
SPIN Spine Injury Solutions 3
ATIF ATIF Holdings 0
BYLG Bylog Group 0
ADMEN ADM Endeavors 0
HCAT 2019-06-30
Part I. Financial Information
Item 1. Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II. Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 6. Exhibits
EX-10.1 exhibit101-10qxnonxemp.htm
EX-31.1 exhibit311-10qxcertifi.htm
EX-31.2 exhibit312-10qxcertifi.htm
EX-32.1 exhibit321-10qxcertifi.htm

Health Catalyst Earnings 2019-06-30

HCAT 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Document
false--12-31Q220190001636422P1Y0.0010.001500000000477935650024263620390747793565002426362039070.06250.0050.10.0750.0050P5YP10YP2YP2Y000210000130001150000.0012500000000P5YP3YP3YP1YP2YP2Y0.4760.4640.4450.4380.0280.0250.0250.024483213450552040.530600031800021.20.0010.0010.00100035874994986287479400733146126030749437787P10Y 0001636422 2019-01-01 2019-06-30 0001636422 2019-08-16 0001636422 2019-06-30 0001636422 2018-12-31 0001636422 hcat:TechnologyMember 2018-04-01 2018-06-30 0001636422 2018-04-01 2018-06-30 0001636422 2018-01-01 2018-06-30 0001636422 hcat:TechnologyMember 2019-04-01 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2019-01-01 2019-06-30 0001636422 2019-04-01 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2018-04-01 2018-06-30 0001636422 hcat:TechnologyMember 2018-01-01 2018-06-30 0001636422 hcat:ProfessionalServicesMember 2018-01-01 2018-06-30 0001636422 hcat:TechnologyMember 2019-01-01 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2019-04-01 2019-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001636422 2019-03-31 0001636422 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001636422 us-gaap:CommonStockMember 2019-03-31 0001636422 us-gaap:CommonStockMember 2019-06-30 0001636422 us-gaap:RetainedEarningsMember 2019-03-31 0001636422 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001636422 us-gaap:RetainedEarningsMember 2019-06-30 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001636422 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001636422 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001636422 us-gaap:CommonStockMember 2018-12-31 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001636422 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001636422 us-gaap:RetainedEarningsMember 2018-12-31 0001636422 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001636422 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001636422 us-gaap:CommonStockMember 2018-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001636422 us-gaap:RetainedEarningsMember 2018-06-30 0001636422 us-gaap:CommonStockMember 2017-12-31 0001636422 us-gaap:RetainedEarningsMember 2017-12-31 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001636422 2018-06-30 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001636422 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001636422 2017-12-31 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001636422 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001636422 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001636422 us-gaap:RetainedEarningsMember 2018-03-31 0001636422 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001636422 2018-03-31 0001636422 us-gaap:CommonStockMember 2018-03-31 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001636422 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001636422 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-06-30 0001636422 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-06-30 0001636422 hcat:CustomerRelationshipsAndContractsMember 2019-01-01 2019-06-30 0001636422 us-gaap:TrademarksMember 2019-01-01 2019-06-30 0001636422 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-29 2019-07-29 0001636422 us-gaap:IPOMember 2019-06-30 0001636422 srt:ScenarioForecastMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-29 2019-07-29 0001636422 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-29 0001636422 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2019-07-29 2019-07-29 0001636422 hcat:InternalUseSoftwareMember 2019-01-01 2019-06-30 0001636422 us-gaap:SubsequentEventMember 2019-07-29 2019-07-29 0001636422 srt:MinimumMember us-gaap:ComputerEquipmentMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember us-gaap:ComputerEquipmentMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-06-30 0001636422 us-gaap:SubsequentEventMember 2019-07-10 2019-07-10 0001636422 hcat:MedicityLLCMember 2017-01-01 2017-12-31 0001636422 hcat:MedicityLLCMember 2018-01-01 2018-12-31 0001636422 hcat:MedicityLLCMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0001636422 hcat:MedicityLLCMember 2019-01-01 2019-06-30 0001636422 hcat:MedicityLLCMember 2018-06-29 2018-12-31 0001636422 hcat:MedicityLLCMember 2019-04-01 2019-06-30 0001636422 hcat:MedicityLLCMember 2018-06-29 0001636422 hcat:MedicityLLCMember hcat:FairValueAdjustmentToDeferredRevenuesAmortizationOfAcquiredIntangibleAssetsAndAcquisitionRelatedCostsMember 2018-01-01 2018-12-31 0001636422 hcat:MedicityLLCMember us-gaap:TrademarksMember 2019-01-01 2019-06-30 0001636422 hcat:MedicityLLCMember 2018-06-29 2018-06-29 0001636422 hcat:MedicityLLCMember hcat:SeriesERedeemableConvertiblePreferredStockMember 2018-06-29 0001636422 hcat:MedicityLLCMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001636422 hcat:MedicityLLCMember hcat:FairValueAdjustmentToDeferredRevenuesAmortizationOfAcquiredIntangibleAssetsAndAcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0001636422 srt:MaximumMember hcat:MedicityLLCMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-06-30 0001636422 hcat:MedicityLLCMember us-gaap:TrademarksMember 2018-06-29 0001636422 hcat:MedicityLLCMember us-gaap:DevelopedTechnologyRightsMember 2018-06-29 0001636422 hcat:MedicityLLCMember us-gaap:CustomerRelatedIntangibleAssetsMember 2018-06-29 0001636422 hcat:MedicityLLCMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-06-29 0001636422 srt:MaximumMember hcat:MedicityLLCMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember hcat:MedicityLLCMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember hcat:MedicityLLCMember 2019-01-01 2019-06-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2019-04-01 2019-06-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2018-04-01 2018-06-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-06-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-06-30 0001636422 hcat:OnetimeTechnologyMember 2019-01-01 2019-06-30 0001636422 hcat:OnetimeTechnologyMember 2019-04-01 2019-06-30 0001636422 hcat:RecurringTechnologyMember 2018-04-01 2018-06-30 0001636422 hcat:RecurringTechnologyMember 2019-01-01 2019-06-30 0001636422 hcat:RecurringTechnologyMember 2019-04-01 2019-06-30 0001636422 hcat:RecurringTechnologyMember 2018-01-01 2018-06-30 0001636422 hcat:OnetimeTechnologyMember 2018-04-01 2018-06-30 0001636422 hcat:OnetimeTechnologyMember 2018-01-01 2018-06-30 0001636422 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001636422 us-gaap:TrademarksMember 2018-12-31 0001636422 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0001636422 hcat:CustomerRelationshipsAndContractsMember 2018-12-31 0001636422 hcat:TechnologyMember 2018-12-31 0001636422 hcat:ProfessionalServicesMember 2018-12-31 0001636422 hcat:TechnologyMember 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2019-06-30 0001636422 hcat:CustomerRelationshipsAndContractsMember 2019-06-30 0001636422 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-06-30 0001636422 us-gaap:TrademarksMember 2019-06-30 0001636422 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001636422 hcat:AssetsHeldUnderFinanceLeasesMember 2018-12-31 0001636422 us-gaap:SoftwareDevelopmentMember 2019-06-30 0001636422 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-06-30 0001636422 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001636422 us-gaap:ComputerEquipmentMember 2019-06-30 0001636422 hcat:AssetsHeldUnderFinanceLeasesMember 2019-06-30 0001636422 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001636422 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001636422 us-gaap:ComputerEquipmentMember 2018-12-31 0001636422 us-gaap:SoftwareDevelopmentMember 2018-12-31 0001636422 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001636422 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:CommercialPaperMember 2018-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:MoneyMarketFundsMember 2018-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 hcat:ShortTermMarketableSecurityMember 2018-12-31 0001636422 us-gaap:CashEquivalentsMember 2018-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:MoneyMarketFundsMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember 2019-06-30 0001636422 us-gaap:CommercialPaperMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:MoneyMarketFundsMember 2019-06-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-06-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001636422 hcat:TermLoanMember 2018-12-31 0001636422 us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001636422 hcat:LoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2016-06-01 2016-06-30 0001636422 hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-01-01 2019-06-30 0001636422 hcat:MezzanineLoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2017-10-01 2017-10-31 0001636422 srt:MinimumMember hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-02-06 0001636422 srt:MinimumMember hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-06-30 0001636422 hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-02-06 2019-02-06 0001636422 hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-02-06 0001636422 srt:MaximumMember hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-02-06 0001636422 us-gaap:RevolvingCreditFacilityMember hcat:SiliconValleyBankMember 2019-02-06 2019-02-06 0001636422 hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-06 2019-02-06 0001636422 hcat:LoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2019-02-06 0001636422 hcat:TermLoanMember hcat:SiliconValleyBankMember 2019-02-06 2019-02-06 0001636422 srt:MaximumMember hcat:SeniorTermLoanMember hcat:OrbiMedRoyaltyOpportunitiesIILPMember 2019-06-30 0001636422 2016-06-01 2016-06-30 0001636422 hcat:MezzanineLoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2017-10-31 0001636422 hcat:MezzanineLoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2018-10-01 2018-10-31 0001636422 hcat:LoanandSecurityAgreementMember hcat:SiliconValleyBankMember 2016-06-30 0001636422 hcat:TermLoanMember 2019-06-30 0001636422 us-gaap:RevolvingCreditFacilityMember 2019-06-30 0001636422 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2019-06-30 0001636422 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2019-06-30 0001636422 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-30 0001636422 hcat:TermLoanMember us-gaap:PrimeRateMember 2018-12-31 0001636422 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2018-12-31 0001636422 hcat:RepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedfromTeamMembersMember 2019-01-01 2019-06-30 0001636422 hcat:TeamMemberMember 2018-06-30 0001636422 hcat:RepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedfromTeamMembersMember 2019-01-01 2019-06-30 0001636422 hcat:TeamMemberMember 2018-01-01 2018-06-30 0001636422 hcat:MezzanineLoanandSecurityAgreementMember us-gaap:WarrantMember 2017-10-31 0001636422 us-gaap:StockCompensationPlanMember 2018-12-31 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2018-12-31 0001636422 us-gaap:EmployeeStockOptionMember 2018-12-31 0001636422 us-gaap:EmployeeStockOptionMember 2019-06-30 0001636422 us-gaap:WarrantMember 2018-12-31 0001636422 us-gaap:StockCompensationPlanMember 2019-06-30 0001636422 us-gaap:WarrantMember 2019-06-30 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2019-06-30 0001636422 hcat:MezzanineLoanandSecurityAgreementMember 2017-10-31 0001636422 us-gaap:SeriesBPreferredStockMember 2018-06-30 0001636422 us-gaap:SeriesBPreferredStockMember 2019-06-30 0001636422 us-gaap:SeriesFPreferredStockMember 2019-01-01 2019-06-30 0001636422 us-gaap:SeriesFPreferredStockMember 2019-06-30 0001636422 us-gaap:SeriesEPreferredStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:SeriesAPreferredStockMember 2018-06-30 0001636422 hcat:MedicityLLCMember us-gaap:SeriesEPreferredStockMember 2018-06-01 2018-06-30 0001636422 us-gaap:SeriesDPreferredStockMember 2019-06-30 0001636422 us-gaap:SeriesDPreferredStockMember 2018-06-30 0001636422 us-gaap:SeriesCPreferredStockMember 2019-06-30 0001636422 us-gaap:SeriesFPreferredStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001636422 hcat:MedicityLLCMember us-gaap:SeriesEPreferredStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:SeriesCPreferredStockMember 2018-06-30 0001636422 hcat:MedicityLLCMember us-gaap:SeriesEPreferredStockMember 2018-06-29 0001636422 us-gaap:SeriesFPreferredStockMember 2018-06-30 0001636422 us-gaap:SeriesEPreferredStockMember 2019-06-30 0001636422 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001636422 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001636422 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001636422 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001636422 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001636422 us-gaap:PerformanceSharesMember 2018-01-01 2018-06-30 0001636422 us-gaap:PerformanceSharesMember 2018-04-01 2018-06-30 0001636422 2018-01-01 2018-12-31 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001636422 us-gaap:PerformanceSharesMember 2019-04-01 2019-06-30 0001636422 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001636422 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001636422 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001636422 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001636422 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember 2019-01-01 2019-06-30 0001636422 srt:MinimumMember 2018-01-01 2018-06-30 0001636422 srt:MinimumMember 2019-01-01 2019-06-30 0001636422 srt:MaximumMember 2018-01-01 2018-06-30 0001636422 2019-07-01 2019-06-30 0001636422 srt:DirectorMember 2019-01-01 2019-06-30 0001636422 srt:DirectorMember 2018-12-31 0001636422 srt:DirectorMember 2018-04-01 2018-06-30 0001636422 srt:DirectorMember 2019-04-01 2019-06-30 0001636422 srt:DirectorMember 2018-01-01 2018-06-30 0001636422 srt:DirectorMember 2019-06-30 0001636422 hcat:TechnologyMember 2018-01-01 2018-06-30 0001636422 hcat:ProfessionalServicesMember 2019-04-01 2019-06-30 0001636422 hcat:TechnologyMember 2018-04-01 2018-06-30 0001636422 hcat:ProfessionalServicesMember 2018-01-01 2018-06-30 0001636422 hcat:TechnologyMember 2019-01-01 2019-06-30 0001636422 hcat:TechnologyMember 2019-04-01 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2019-01-01 2019-06-30 0001636422 hcat:ProfessionalServicesMember 2018-04-01 2018-06-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2018-04-01 2018-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2018-01-01 2018-06-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-06-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2018-04-01 2018-06-30 0001636422 us-gaap:OperatingSegmentsMember 2019-01-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember 2018-04-01 2018-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2019-01-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2019-01-01 2019-06-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2019-04-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2018-04-01 2018-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2019-04-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2019-04-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember 2018-01-01 2018-06-30 0001636422 us-gaap:OperatingSegmentsMember 2019-04-01 2019-06-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2018-01-01 2018-06-30 0001636422 us-gaap:ScenarioAdjustmentMember 2019-06-30 0001636422 srt:ProFormaMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-29 2019-07-29 0001636422 srt:ProFormaMember 2019-06-30 iso4217:USD xbrli:pure hcat:segment hcat:Sergment xbrli:shares iso4217:USD xbrli:shares
       .
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 10-Q
________________
(Mark One)
   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019
Or
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission File Number: 001-38993
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
________________
Delaware
 
45-3337483
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
3165 Millrock Drive #400
Salt Lake City, UT 84121
(Address of principal executive offices, including zip code)

(801) 708-6800
(Registrant’s telephone number, including area code)
________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of exchange on which registered
Common Stock, par value $0.001 per share
 
HCAT
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated Filer
Emerging growth company
Non-accelerated Filer
Smaller reporting company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
As of August 16, 2019, the Registrant had 36,494,678 shares of common stock outstanding.
 




HEALTH CATALYST, INC.

Table of Contents

 
 
Page
 
 
 
 
 
 
 
 
Special Note Regarding Forward-looking Statements
As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to “Health Catalyst,” “we,” “us,” “our,” “the Company,” and similar references refer to Health Catalyst, Inc. and its consolidated subsidiaries. This Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements, which are subject to a number of risks, uncertainties, and assumptions, generally relate to future events or our future financial or operating performance. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “target,” “project,” “contemplate,” or the negative version of these words and other comparable terminology that concern our expectations, strategy, plans, intentions, or projections. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: 
our ability to attract new customers and retain and expand our relationships with existing customers;
our ability to expand our service offerings and develop new platform features;
our future financial performance, including trends in revenue, costs of revenue, gross margin, and operating expenses;
our ability to compete successfully in competitive markets;


1



our ability to respond to rapid technological changes;
our expectations and management of future growth;
our ability to enter new markets and manage our expansion efforts, particularly internationally;
our ability to attract and retain key employees, whom we refer to as team members;
our ability to effectively and efficiently protect our brand;
our ability to timely scale and adapt our infrastructure;
our ability to maintain, protect, and enhance our intellectual property and not infringe upon others’ intellectual property; and
our ability to successfully identify, acquire, and integrate companies and assets.
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q and as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission (the SEC). Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements and you should not place undue reliance on our forward-looking statements.
The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law.
You should read this Quarterly Report on Form 10-Q in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2018, included in our prospectus dated July 24, 2019 (File No. 333-232400) as filed with the Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4) under the Securities Act of 1933, or the Prospectus.


2



Part I. Financial Information
Item 1.  Financial Statements


HEALTH CATALYST, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
 
As of
June 30,
 
As of
December 31,
 
2019
 
2018
 
(unaudited)
 
 
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
20,819

 
$
28,431

Short-term investments
33,257

 
4,761

Accounts receivable, net(1)
34,472

 
27,696

Deferred costs
845

 
649

Prepaid expenses and other assets
5,632

 
5,321

Total current assets
95,025

 
66,858

Property and equipment, net
4,180

 
4,676

Intangible assets, net
27,538

 
28,304

Operating lease right-of-use assets
5,198

 
6,344

Other assets
4,041

 
1,099

Goodwill
3,694

 
3,694

Total assets
$
139,676

 
$
110,975

Liabilities, redeemable convertible preferred stock, and stockholders’ deficit
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
3,035

 
$
1,812

Accrued liabilities
8,107

 
9,203

Acquisition-related consideration payable(1)
2,200

 
2,172

Deferred revenue
34,405

 
24,755

Operating lease liabilities
2,761

 
2,577

Current portion of long-term debt

 
1,287

Total current liabilities
50,508

 
41,806

Long-term debt, net of current portion
47,635

 
18,814

Acquisition-related consideration payable, net of current portion(1)
2,944

 
3,770

Deferred revenue, net of current portion
7,306

 
7,280

Operating lease liabilities, net of current portion
3,206

 
4,228

Other liabilities
652

 

Total liabilities
112,251

 
75,898

Commitments and contingencies (Note 15)

 



3


Redeemable convertible preferred stock, $0.001 par value; 46,505,028 and 45,427,441 shares authorized as of June 30, 2019 and December 31, 2018, respectively; 23,151,481 and 22,713,694 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively; aggregated liquidation preference of $318,381 and $306,192 as of June 30, 2019 and December 31, 2018, respectively
584,574

 
409,845

Stockholders’ deficit:
 
 
 
Common stock, $0.001 par value; 73,642,899 and 72,565,312 shares authorized as of June 30, 2019 and December 31, 2018, respectively; 5,002,426 and 4,779,356 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
5

 
5

Additional paid-in capital

 

Accumulated deficit
(557,163
)
 
(374,772
)
Accumulated other comprehensive income (loss)
9

 
(1
)
Total stockholders’ deficit
(557,149
)
 
(374,768
)
Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit
$
139,676

 
$
110,975

____________________
(1)
Includes amounts attributable to related party transactions. See Note 17 for further details.
The accompanying notes are an integral part of these condensed consolidated financial statements


4


HEALTH CATALYST, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Revenue(1):
 
 
 
 
 
 
 
Technology
$
20,085

 
$
10,725

 
$
40,233

 
$
20,176

Professional services
16,719

 
12,265

 
31,784

 
23,446

Total revenue
36,804

 
22,990

 
72,017

 
43,622

Cost of revenue, excluding depreciation and amortization(1):
 
 
 
 
 
 
 
Technology
7,044

 
3,291

 
13,796

 
6,650

Professional services
10,666

 
9,227

 
21,240

 
17,478

Total cost of revenue, excluding depreciation and amortization
17,710

 
12,518

 
35,036

 
24,128

Operating expenses(1):
 
 
 
 
 
 
 
Sales and marketing
10,385

 
12,004

 
20,858

 
18,725

Research and development
9,710

 
8,487

 
19,732

 
17,192

General and administrative
6,146

 
7,241

 
12,320

 
11,143

Depreciation and amortization
2,216

 
1,551

 
4,528

 
3,101

Total operating expenses
28,457

 
29,283

 
57,438

 
50,161

Loss from operations
(9,363
)
 
(18,811
)
 
(20,457
)
 
(30,667
)
Loss on extinguishment of debt

 

 
(1,670
)
 

Interest and other expense, net
(1,320
)
 
(506
)
 
(2,265
)
 
(1,015
)
Loss before income taxes
(10,683
)
 
(19,317
)
 
(24,392
)
 
(31,682
)
Income tax provision (benefit)
11

 
7

 
22

 
(149
)
Net loss
$
(10,694
)
 
$
(19,324
)
 
$
(24,414
)
 
$
(31,533
)
Less: accretion (reversal of accretion) of redeemable convertible preferred stock
98,641

 
(2,078
)
 
162,656

 
(12,559
)
Net loss attributable to common stockholders
$
(109,335
)
 
$
(17,246
)
 
$
(187,070
)
 
$
(18,974
)
Net loss per share attributable to common stockholders, basic and diluted
$
(21.98
)
 
$
(3.53
)
 
$
(38.29
)
 
$
(3.89
)
Weighted-average shares outstanding used in calculating net loss per share attributable to common stockholders, basic and diluted
4,975

 
4,888

 
4,885

 
4,878

__________________
(1)
Includes amounts attributable to related party transactions. See Note 17 for further details.
The accompanying notes are an integral part of these condensed consolidated financial statements


5


HEALTH CATALYST, INC.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
(unaudited)

 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Net Loss
$
(10,694
)
 
$
(19,324
)
 
$
(24,414
)
 
$
(31,533
)
 
 
 
 
 
 
 
 
Other comprehensive loss:
 
 
 
 
 
 
 
Unrealized gain (loss) on investments
7

 
14

 
10

 
(1
)
Comprehensive loss
$
(10,687
)
 
$
(19,310
)
 
$
(24,404
)
 
$
(31,534
)
The accompanying notes are an integral part of these condensed consolidated financial statements


6


HEALTH CATALYST, INC.
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit
(in thousands, except share data)
(unaudited)
 
Three Months Ended June 30, 2019
 
Redeemable Convertible Preferred Stock
 
 
Common Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive Income
 
Total Stockholders’ Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
 
 
 
Balance as of March 31, 2019
23,151,481

 
$
485,933

 
 
4,873,914

 
$
5

 
$

 
$
(450,043
)
 
$
2

 
$
(450,036
)
Exercise of stock options

 

 
 
128,512

 

 
817

 

 

 
817

Stock-based compensation

 

 
 

 

 
1,398

 

 

 
1,398

Net loss

 

 
 

 

 

 
(10,694
)
 

 
(10,694
)
Other comprehensive gain

 

 
 

 

 

 

 
7

 
7

Accretion of redeemable convertible preferred stock

 
98,641

 
 

 

 
(2,215
)
 
(96,426
)
 

 
(98,641
)
Balance as of June 30, 2019
23,151,481

 
$
584,574

 
 
5,002,426

 
$
5

 
$

 
$
(557,163
)
 
$
9

 
$
(557,149
)
 
Six Months Ended June 30, 2019
 
Redeemable Convertible Preferred Stock
 
 
Common Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive (Loss) Income
 
Total Stockholders’ Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
 
 
 
Balance as of December 31, 2018
22,713,694

 
$
409,845

 
 
4,779,356

 
$
5

 
$

 
$
(374,772
)
 
$
(1
)
 
$
(374,768
)
Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $115
437,787

 
12,073

 
 

 

 

 

 

 

Exercise of stock options

 

 
 
223,070

 

 
1,625

 

 

 
1,625

Stock-based compensation

 

 
 

 

 
3,054

 

 

 
3,054

Net loss

 

 
 

 

 

 
(24,414
)
 

 
(24,414
)
Other comprehensive gain

 

 
 

 

 

 

 
10

 
10

Accretion of redeemable convertible preferred stock

 
162,656

 
 

 

 
(4,679
)
 
(157,977
)
 

 
(162,656
)
Balance as of June 30, 2019
23,151,481

 
$
584,574

 
 
5,002,426

 
$
5

 
$

 
$
(557,163
)
 
$
9

 
$
(557,149
)
The accompanying notes are an integral part of these condensed consolidated financial statements




7


HEALTH CATALYST, INC.
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit
(in thousands, except share data)
(unaudited)
 
Three Months Ended June 30, 2018
 
Redeemable Convertible Preferred Stock
 
 
Common Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive Loss
 
Total Stockholders’ Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
 
 
 
Balance as of March 31, 2018
21,298,468

 
$
315,085

 
 
4,873,095

 
$
5

 
$
11,609

 
$
(271,677
)
 
$
(27
)
 
$
(260,090
)
Issuance of Series E redeemable convertible preferred stock, net of issuance costs of $10
1,415,226

 
32,242

 
 

 

 

 

 

 

Repurchase of common stock

 

 
 
(798,372
)
 
(1
)
 
(8,711
)
 
 
 
 
 
(8,712
)
Exercise of stock options

 

 
 
596,682

 
1

 
2,505

 

 

 
2,506

Stock-based compensation

 

 
 

 

 
914

 

 

 
914

Net loss

 

 
 

 

 

 
(19,324
)
 

 
(19,324
)
Other comprehensive loss

 

 
 

 

 

 

 
14

 
14

Reversal of accretion of redeemable convertible preferred stock

 
(2,078
)
 
 

 

 
2,078

 

 

 
2,078

Balance as of June 30, 2018
22,713,694

 
$
345,249

 
 
4,671,405

 
$
5

 
$
8,395

 
$
(291,001
)
 
$
(13
)
 
$
(282,614
)
 
Six Months Ended June 30, 2018
 
Redeemable Convertible Preferred Stock
 
 
Common Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive Loss
 
Total Stockholders’ Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
 
 
 
Balance as of December 31, 2017
21,109,771

 
$
321,569

 
 
4,853,841

 
$
5

 
$

 
$
(259,468
)
 
$
(12
)
 
$
(259,475
)
Issuance of Series E redeemable convertible preferred stock, net of issuance costs of $13
1,603,923

 
36,239

 
 

 

 

 

 

 

Repurchase of common stock

 

 
 
(798,372
)
 
(1
)
 
(8,711
)
 
 
 
 
 
(8,712
)
Exercise of stock options

 

 
 
615,936

 
1

 
2,593

 

 

 
2,594

Stock-based compensation

 

 
 

 

 
1,954

 

 

 
1,954

Net loss

 

 
 

 

 

 
(31,533
)
 

 
(31,533
)
Other comprehensive loss

 

 
 

 

 

 

 
(1
)
 
(1
)
Reversal of accretion of redeemable convertible preferred stock

 
(12,559
)
 
 

 

 
12,559

 

 

 
12,559

Balance as of June 30, 2018
22,713,694

 
$
345,249

 
 
4,671,405

 
$
5

 
$
8,395

 
$
(291,001
)
 
$
(13
)
 
$
(282,614
)
The accompanying notes are an integral part of these condensed consolidated financial statements


8


HEALTH CATALYST, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
 
Six Months Ended June 30,
 
2019
 
2018
Cash flows from operating activities
 
 
 
Net loss
$
(24,414
)
 
$
(31,533
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
4,528

 
3,101

Loss on extinguishment of debt
1,670

 

Amortization of debt discount and issuance costs
516

 
258

Investment discount and premium amortization
(274
)
 
(74
)
Change in fair value of warrant liability

 
(35
)
Gain on sale of property and equipment
(34
)
 
(15
)
Stock-based compensation expense
3,054

 
1,954

Change in operating assets and liabilities:
 
 
 
Accounts receivable, net
(6,776
)
 
(2,825
)
Deferred costs
(196
)
 
358

Prepaid expenses and other assets
(55
)
 
(1,500
)
Operating lease right-of-use assets
1,146

 
(1,239
)
Accounts payable, accrued liabilities, and other liabilities
(1,644
)
 
2,810

Deferred revenue
9,676

 
6,237

Operating lease liabilities
(838
)
 
1,096

Net cash used in operating activities
(13,641
)
 
(21,407
)
 
 
 
 
Cash flows from investing activities
 
 
 
Purchases of property and equipment
(1,063
)
 
(521
)
Proceeds from the sale of property and equipment
38

 
15

Purchase of short-term investments
(40,509
)
 
(2,679
)
Proceeds from the sale and maturity of short-term investments
12,297

 
14,200

Purchase of intangible assets
(977
)
 
(18
)
Net cash (used in) provided by investing activities
(30,214
)
 
10,997

 
 
 
 
Cash flows from financing activities
 
 
 
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs
12,073

 
33,987

Proceeds from exercise of stock options
1,625

 
2,594

Repurchase of common stock

 
(8,712
)
Payment of SVB line of credit and mezzanine loan
(21,821
)
 

Proceeds from credit facilities, net of debt issuance costs
47,169

 

Payments of acquisition-related consideration
(773
)
 
(11,136
)
Payments of deferred offering costs
(2,030
)
 



9


Net cash provided by financing activities
36,243

 
16,733

Net (decrease) increase in cash and cash equivalents
(7,612
)
 
6,323

 
 
 
 
Cash and cash equivalents at beginning of period
28,431

 
22,978

Cash and cash equivalents at end of period
$
20,819

 
$
29,301

 
 
 
 
Supplemental disclosures of non-cash investing and financing information
 
 
 
Redeemable convertible preferred stock accretion (reversal of accretion)
$
162,656

 
$
(12,559
)
Deferred offering costs included in accounts payable and accrued liabilities
1,168

 

Series E redeemable convertible preferred stock allocated to business combination

 
2,252

Purchase of intangible assets included in accounts payable and accrued liabilities
1,304

 

Purchase of property and equipment included in accounts payable and accrued liabilities
10

 
15

Supplemental disclosures of cash flow information related to leases
 
 
 
Cash paid for operating lease liabilities in operating cash flows
$
1,605

 
$
1,171

Operating lease right-of-use assets obtained in exchange for operating lease obligations
581

 
2,182

The accompanying notes are an integral part of these condensed consolidated financial statements


10

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)


1. Description of Business and Summary of Significant Accounting Policies
Nature of operations
Health Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011.
We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises a cloud-based data platform, analytics software, and professional services expertise. Our customers, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
Basis of presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2018 included in the Prospectus.
Interim Unaudited Condensed Consolidated Financial Statements
The accompanying interim condensed consolidated balance sheet as of June 30, 2019, the interim condensed consolidated statements of operations for the three and six months ended June 30, 2019 and 2018, the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders' deficit for the three and six months ended June 30, 2019, and the interim condensed consolidated statements of cash flows for the six months ended June 30, 2019 and 2018 are unaudited. The condensed consolidated balance sheet as of December 31, 2018 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year or any other period.
Initial Public Offering
On July 29, 2019, we closed our initial public offering of common stock (IPO) in which we issued and sold 8,050,000 shares (inclusive of the underwriters’ over-allotment option to purchase 1,050,000 shares, which was exercised on July 25, 2019) of common stock at $26.00 per share. We received net proceeds of $194.6 million after deducting underwriting discounts and commissions and before deducting estimated offering costs of $4.4 million, of which $3.2 million was included in other assets as of June 30, 2019. Upon the closing of our IPO, all shares of our outstanding redeemable convertible preferred stock converted into 23,151,481 shares of common stock on a one-for-one basis.
The shares and proceeds from our IPO, the underwriters’ exercise of their option to purchase additional shares, and the conversion of our outstanding redeemable convertible stock into shares of common stock are not reflected in the condensed consolidated financial statements as of and for the three and six months ended June 30, 2019.


11

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

Stock Split
On July 10, 2019, we effected a 1-for-2 reverse stock split of our capital stock. We have adjusted all references to share and per share amounts in the accompanying consolidated financial statements and notes to reflect the reverse stock split.
Principles of consolidation
The consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Use of estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for doubtful accounts, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, common stock warrants, redeemable convertible preferred stock accretion, stock-based compensation, and tax uncertainties. Actual results could differ from those estimates.
Segment reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (the CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.
Net loss per share
We compute basic and diluted net loss per share in conformity with the two-class method required for participating securities. Redeemable convertible preferred stock and common stock are considered participating securities for purposes of this calculation. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to holders of common stock. However, the two-class method does not impact the net loss per share, as we are in a loss position for each of the periods presented and shares of redeemable convertible preferred stock do not participate in losses.
Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding. Net loss attributable to common stockholders is computed as net loss less accretion (reversal of accretion) of redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, stock options and warrants to purchase common stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is antidilutive.
Revenue recognition
We recognize revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (Topic 606). We derive our revenues primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps:


12

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

Identification of the contract, or contracts, with a customer;
Identification of the performance obligations in the contract;
Determination of the transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, we satisfy the performance obligation.
We recognize revenue net of any taxes collected from customers and subsequently remitted to governmental authorities.
Technology revenue
Technology revenue primarily consists of subscription fees charged to customers for access to use our technology. We provide customers access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide customers the right to take possession of the technology or contain a significant penalty if the customer were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the customer. Most of our subscription contracts have up to a three-year term, of which the vast majority are terminable after one year upon 90 days’ notice.
Subscriptions that allow the customer to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the customer. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the customer.
We also have certain perpetual license arrangements. Revenue from these arrangements is recognized at a point in time upon delivery of the software.
Technology revenue also includes maintenance and support revenue which generally includes bug fixes, updates, and support services. Revenue related to maintenance and support is recognized over the contract term beginning on the date that the service is made available to the customer.
Professional services revenue
Professional services revenue primarily includes analytics services, implementation services, strategic advisory services, and improvement services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our customers on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our customer. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the “right to invoice” practical expedient.
Contracts with multiple performance obligations
Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis.


13

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include customer demographics and the types of users.
Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we use the residual estimation method due to a limited number of standalone transactions and/or prices that are highly variable.
Variable consideration
We have also entered into at-risk and shared savings arrangements with certain customers whereby we receive variable consideration based on the achievement of measurable improvements which may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved.
Contract balances
Contract assets resulting from services performed prior to invoicing customers are recorded as unbilled accounts receivable and are presented on the consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of June 30, 2019 and December 31, 2018, the unbilled accounts receivable included in accounts receivable on our consolidated balance sheets was $3.3 million and $3.4 million, respectively.
We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the customer. As of June 30, 2019 and December 31, 2018, the total of current and non-current deferred revenue on our consolidated balance sheets was $41.7 million and $32.0 million, respectively.
Cost of revenue, excluding depreciation and amortization
Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue excludes costs related to depreciation and amortization.
We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. As of June 30, 2019 and December 31, 2018, we had deferred contract fulfillment costs of $0.8 million and $0.6 million, respectively.
Cash and cash equivalents
We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.


14

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

Short-term investments
Our investment policy limits investments to highly-rated instruments that mature in less than 12 months. We classify our short-term investments as available for sale.
Accounts receivable
Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for doubtful accounts based on the probability of future collections. When we become aware of circumstances that may decrease the likelihood of collections, we record a specific allowance against amounts due, which reduces the receivable amount to the amount reasonably believed to be collected. For all other customers, we determine and periodically adjust the allowance based on historical loss patterns and current receivables aging. As of June 30, 2019 and December 31, 2018, we had an allowance for doubtful accounts of $0.4 million and $0.5 million, respectively.
Property and equipment
Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:
Computer equipment
2-3 years
Furniture and fixtures
3 years
Leasehold improvements
Lesser of lease term or estimated useful life
Computer software
2-3 years
Capitalized internal-use software costs
3 years

When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining life of the primary long-lived asset in that group plus any residual value. If the carrying amount of the asset group exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of those assets. We did not incur any long-lived impairment charges for the three and six months ended June 30, 2019 and 2018.
Intangible assets
Intangible assets include developed technologies, customer relationships, customer contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets’ estimated useful lives. The estimated useful life of each asset category is as follows:
Developed technologies
2-10 years
Customer relationships and contracts
6 years
Computer software licenses
2-5 years
Trademarks
2 years



15

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

Goodwill
We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill is assessed for impairment annually or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. The first step of the goodwill impairment test compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the affected reporting unit’s goodwill with the carrying value of that goodwill. There was no impairment of goodwill for the three and six months ended June 30, 2019 and 2018
Deferred offering costs
Deferred offering costs, which consist of legal, consulting, banking, and accounting fees directly attributable to the IPO, are capitalized and will be offset against proceeds upon the consummation of the IPO. As of June 30, 2019 and December 31, 2018, our capitalized deferred offering costs of $3.2 million and $0.1 million, respectively, were included in other assets within the consolidated balance sheets.
Common stock warrants
We account for freestanding warrants to purchase shares of our common stock that are not considered indexed to our own stock as warrant liabilities on our consolidated balance sheets until the point in time that they qualify for equity classification. We record liability-classified common stock warrants at their estimated fair value because they are free standing and the number of shares exercisable increases as we make advances on our credit facility.
At the end of each reporting period, we record the change in the estimated fair value of the warrants to purchase common stock as a change in fair value of warrant liability within interest and other expense, net in our consolidated statements of operations. We reclassify the warrants from liability-classified to equity-classified as exercise contingencies related to the warrants become resolved.
Business combinations
We account for an acquisition as a business combination if we obtain control of a business. Assets and liabilities acquired in a business combination generally are recorded at fair value and any associated acquisition costs are expensed as incurred in general and administrative expenses.
Advertising costs
All advertising costs are expensed as incurred. We recorded advertising costs of $0.4 million and $0.6 million for the three months ended June 30, 2019 and 2018, respectively, and $1.1 million and $1.1 million for the six months ended June 30, 2019 and 2018, respectively.
Development costs and internal-use software
For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential.
We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our customers on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use.


16

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life of three years.
Stock-based compensation
Stock-based awards, including stock options and restricted stock units (RSUs), are measured and recognized in the consolidated financial statements based on the fair value of the award on the grant date. For awards subject to performance conditions, we will record expense when the performance condition becomes probable. We record forfeitures of stock-based awards as the actual forfeitures occur.
We estimate the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. We have issued two types of employee stock-based awards, standard and two-tier. Our standard stock-based awards vest solely on a service-based condition.  For these awards, we recognize stock-based compensation expense on a straight-line basis over the vesting period. Two-tier employee stock-based awards, contain both a service-based condition and performance condition, defined as the earlier of (i) an acquisition or change in control of the company or (ii) upon the occurrence of an initial public offering by the Company. A change in control event and effective registration event are not deemed probable until consummated; accordingly, no expense is recorded related to two-tier stock-based awards until the performance condition becomes probable of occurring. Awards which contain both service-based and performance conditions are recognized using the accelerated attribution method once the performance condition is probable of occurring. The service-based condition is generally a service period of four years.
Prior to the adoption of ASU No. 2018-07, Compensation — Stock Compensation (ASU 2018-17), which simplifies the accounting for non-employee share-based payment transactions and is discussed below under “Accounting pronouncements adopted,” the fair value measurement date for non-employee awards was the date the performance of services was completed. Upon adoption of ASU 2018-07 on January 1, 2019, the measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award. The impact on our consolidated financial statements was immaterial.
Income taxes
Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and credit carryforwards.
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affect us, including the reduction of the corporate income tax rate to 21%, effective January 1, 2018. We were required to recognize the effect of the tax law changes in the period of enactment. As such, we remeasured our consolidated deferred tax assets and liabilities as of December 31, 2017 to reflect the lower rate and also reassessed the net realizability of those deferred tax assets and liabilities.
A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.
We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement.


17

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

We do not accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because we have NOLs. Significant judgment is required to evaluate uncertain tax positions.
Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, such as the Tax Act, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues.
To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.
Fair value of financial instruments
The carrying amounts reported in the consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of acquisition-related consideration payable, operating lease liabilities, and long-term debt approximate fair value based on interest rates available for debt with similar terms at June 30, 2019 and December 31, 2018. Money market funds and short-term investments are measured at fair value on a recurring basis.
Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
Level 1- Quoted prices in active markets for identical assets or liabilities.
Level 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3- Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease contracts do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
We do not have lease agreements that contain non-lease components, which generally would be accounted for separately.


18

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

Accounting pronouncement adopted
In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting (ASU 2018-07). ASU 2018-07 simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. We adopted ASU 2018-07 as of January 1, 2019 and applied the standard prospectively. The adoption of this standard did not have a material impact on the consolidated financial statements.
Recent accounting pronouncements
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), that changes how companies will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For available-for-sale debt securities, we will be required to record allowances rather than reduce the carrying amount. We are required to adopt ASU 2016-13 for annual and interim reporting periods beginning after December 15, 2019. Based on our preliminary assessment we do not anticipate that the adoption of this ASU will have a material impact on our unaudited condensed consolidated financial statements.
In January 2017, FASB issued ASU 2017-04, Intangibles-Goodwill and Other - Simplifying the Test for Goodwill Impairment (Topic 350), that simplifies how an entity is required to test goodwill for impairment by modifying the second step of the impairment test. The second step measures a goodwill impairment loss by comparing the fair value of a reporting unit to the carrying amount. If the carrying amount of the reporting unit exceeds its fair value, the carrying amount of goodwill is reduced by the excess reporting unit carrying amount up to the carrying amount of the goodwill. Public business entities must adopt ASU 2017-04 for annual or interim goodwill impairment tests in reporting periods beginning after December 15, 2019. The guidance will apply to our reporting requirements in performing goodwill impairment testing; however, we do not anticipate the adoption of this guidance will have a material impact on our unaudited condensed consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information prospectively, including the ranges used to develop significant unobservable inputs for Level 3 fair value measurements, and modifies some disclosure requirements. The new guidance is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not anticipate that the disclosure changes that result from this ASU will be material.
2. Business Combinations
On June 29, 2018, we completed the purchase of Medicity LLC (Medicity) for consideration in the form of shares of Series E redeemable convertible preferred stock with an estimated fair value of $2.3 million from Aetna, Inc. The purchase of Medicity was consummated as part of an integrated transaction that included two components: (1) a $15 million Series E redeemable convertible preferred stock capital raise by us and (2) a business combination where we acquired 100% of the membership interests in Medicity. The acquisition was accounted for as a business combination as specified under ASC 805, Business Combinations. In the integrated transaction, the consideration transferred was allocated between the business combination and the capital raise based on relative values as of June 29, 2018 of the $15 million cash received in the capital raise and the fair value of net identifiable assets received in the business combination.
The fair values of Medicity’s assets and liabilities were determined based on estimates and assumptions that are judgmental in nature, including the timing and amount of projected future cash flows and market-participant discount rates reflecting risks inherent in the future cash flows.


19

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes the acquisition-date fair value of consideration transferred and the assets received and liabilities assumed as part of our acquisition of Medicity (in thousands):
Assets acquired:
 
Accounts receivable
$
7,016

Prepaid expenses
2,735

Property and equipment
1,613

Computer software licenses
2,358

Developed technologies
800

Customer relationships and contracts
600

Trademarks
100

Total assets acquired
15,222

Less liabilities assumed:
 
Accounts payable and other current liabilities
1,970

Deferred revenue
11,000

Total liabilities assumed
12,970

Total assets acquired, net
$
2,252


The intangibles assets acquired were valued utilizing the income approach and include customer relationships, developed technology, and trademarks with estimated useful lives of six years, five years, and two years, respectively. The estimated useful life remaining on software licenses and property and equipment acquired is one to five years.
The following unaudited pro forma information presents our consolidated information as if the acquisition of Medicity had occurred on January 1, 2017 (in thousands, except per share amounts):
 
Year Ended December 31,
 
2017
 
2018
Total pro forma revenues
$
109,739

 
$
128,992

Pro forma net loss
(63,986
)
 
(72,931
)
Pro forma net loss per share attributable to common stockholders, basic and diluted
(13.20
)
 
(15.20
)

The unaudited pro forma information is not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2017 or to project potential results as of any future date or for any future periods. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to our acquisition of Medicity which are included in the pro forma revenues or net loss, as applicable, are attributable to fair value adjustments to deferred revenues, amortization of acquired intangible assets and acquisition-related income tax considerations totaling $11.0 million and $0.5 million in 2017 and 2018, respectively.
The amount of revenue attributable to the acquired business of Medicity that has been included in the consolidated statement of operations subsequent to the June 29, 2018 acquisition date through December 31, 2018 is $12.5 million. The amount of revenue attributable to the acquired business of Medicity for the three and six months ended June 30, 2019 is $6.4 million and $13.0 million, respectively. Loss information for Medicity after the acquisition date through December 31, 2018 is not presented as the Medicity business was integrated into our operations subsequent to the acquisition and is impracticable to quantify. The acquisition provides us with the opportunity to cross-sell to several top health systems and the ability to leverage the Medicity acquired technology to drive change via analytics at the point of care.


20

HEALTH CATALYST, INC.
Notes to the Condensed Consolidated Financial Statements
(unaudited)

3. Revenue
Disaggregation of revenue
The following table represents Health Catalyst’s revenue disaggregated by type of arrangement (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Recurring technology
$
20,085

 
$
10,425

 
$
40,233

 
$
19,538

One-time technology (i.e., perpetual license)

 
300